Leveraging products and finance to reduce risk and improve outcomes for patients and shareholders

Our focus is on diseases which are modulated by the host immune response. We use a virtual biotech model to identify clinical-stage assets for high-value development which is designed to unlock major benefits for both patients and shareholders. Where possible, we leverage our investor capital with non-dilutive funding by directing our effort at disease targets with high national strategic value.

Implicit bannerImplicit banner